Back to Search Start Over

MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy

Authors :
Farzaneh Rezazadeh
Kambiz Varmira
Fariba Maleki
Source :
Molecular Pharmaceutics. 18:1842-1861
Publication Year :
2021
Publisher :
American Chemical Society (ACS), 2021.

Abstract

Mucin 1 (MUC1) is a large, transmembrane mucin glycoprotein overexpressed in most adenocarcinomas and plays an important role in tumor progression. Regarding its cellular distribution, biochemical features, and function, tumor-related MUC1 varies from the MUC1 expressed in normal cells. Therefore, targeting MUC1 for cancer immunotherapy and imaging can exploit the difference between cancerous and normal cells. Radiopharmaceuticals have a potential use as carriers for the delivery of radionuclides to tumors for a diagnostic imaging and radiotherapy. Several radiolabeled targeting molecules like peptides, antibodies, and aptamers have been efficiently demonstrated in detecting and treating cancer by targeting MUC1. This review provides a brief overview of the current status of developments and applications of MUC1-targeted radiopharmaceuticals in cancer imaging and therapy.

Details

ISSN :
15438392 and 15438384
Volume :
18
Database :
OpenAIRE
Journal :
Molecular Pharmaceutics
Accession number :
edsair.doi.dedup.....9b2df97a7d8227b2696ebfc319318232
Full Text :
https://doi.org/10.1021/acs.molpharmaceut.0c01249